Skip to content

COmbiNed eFfIcacy and safety of an eaRly, intensive MAnagement sTrategy with fInerenOne and SGLT2 iNhibitor in patients hospitalized with Heart Failure (CONFIRMATION-HF)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508874-27-00
Acronym
202303CPC
Enrollment
150
Registered
2025-02-27
Start date
2025-12-02
Completion date
Unknown
Last updated
2025-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart condition

Brief summary

The primary endpoint is clinical benefit, defined as a hierarchical composite endpoint of: 1. Time to all-cause mortality 2. Number of total HF events 3. Time to first HF event 4. KCCQ-TSS change from baseline to 6 months of 5 points or greater assessed by the win-ratio method

Detailed description

Secondary endpoints include treatment group difference in: • KCCQ-TSS, mean change from baseline to 6 months • Time to first occurrence of all-cause mortality or HF event (hospitalization for HF or urgent visit due to HF) • Total (first and recurrent) HF events from baseline to 90 days

Interventions

DRUGJardiance 10 mg film-coated tablets
DRUGFinerenone

Sponsors

Colorado Prevention Center
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The primary endpoint is clinical benefit, defined as a hierarchical composite endpoint of: 1. Time to all-cause mortality 2. Number of total HF events 3. Time to first HF event 4. KCCQ-TSS change from baseline to 6 months of 5 points or greater assessed by the win-ratio method

Secondary

MeasureTime frame
Secondary endpoints include treatment group difference in: • KCCQ-TSS, mean change from baseline to 6 months • Time to first occurrence of all-cause mortality or HF event (hospitalization for HF or urgent visit due to HF) • Total (first and recurrent) HF events from baseline to 90 days

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026